A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

Gastroenterology

Volumn 108, Issue 5, 1995, Pages 1470-1478

  Vuoristo, Matti ^a   Fäarkkilä, Martti ^a   Karvonen, Anna Liisa ^b   Leino, Rauli ^c   Lehtola, Juhani ^d   Mäkinen, Judit ^e   Mattila, Jorma ^b   Friman, Claes ^a   Seppälä, Kari ^a   Tuominen, Juhani ^c   Miettinen, Tatu A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e PEIJAS HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; COLCHICINE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; LIVER BIOPSY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

EID: 0028953372     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(95)90696-7     Document Type: Article

References (48)

1. Primary biliary cirrhosis: a model autoimmune disease
2. Primary biliary cirrhosis: paradigm or paradox for autoimmunity
3. Medical treatment of primary biliary cirrhosis
4. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis
5. Asymptomatic primary biliary cirrhosis: a progress report on long-term follow-up and natural history
6. Diminished survival in asymptomatic primary biliary cirrhosis
7. Serum bilirubin: a prognostic factor in primary biliary cirrhosis
8. A prospective trial of colchicine for primary biliary cirrhosis
9. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
10. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial
11. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
12. Ursodiol for the long-term treatment of primary biliary cirrhosis
13. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
14. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
15. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue
16. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
17. Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance
18. Prognosis in primary biliary cirrhosis: model for decision making
19. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin
20. A controlled trial of colchicine in primary biliary cirrhosis
21. Evaluation of colchicine therapy in primary biliary cirrhosis
22. In vitro effect of Cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis
23. Serum interleukin-2 and tumor necrosis factor-α in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4
24. Transforming growth factors β1 and α in chronic liver disease
25. Cholesterol lowering effect of colchicine
26. Intestinal malabsorption induced by oral colchicine
27. Ursodeoxycholic acid (UDCA) is beneficial therapy for patients with primary biliary cirrhosis (PBC)
28. The Canadian multi-centre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
29. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical revelance
30. Immunomodulatory effect of ursodeoxycholic acid on immune responses
31. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid
32. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?
33. Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism
34. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis
35. Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin
36. Carboxyterminal propeptide of type I procollagen
37. Bone disease in patients with primary biliary cirrhosis
38. The effect of ursodeoxycholic acid compared to placebo on lumbar spine bone density in patients with primary biliary cirrhosis
39. Osteocalcin levels before and after ursodeoxycholic acid (UDCA) therapy in primary biliary cirrhosis (PBC)
40. Hyperbilirubinemia inhibits osteoblast proliferation: role of bilirubin in the development of cholestatic osteoporosis
41. Radioimmunoassay for type III procollagen peptide and its application to human liver disease
42. Serum basement membrane and type III procollagen-related antigens in primary biliary cirrhosis
43. Predictive value of serum procollagen-III-peptide for the survival of patients with cirrhosis
44. Serum type III procollagen as a marker in liver transplantation
45. Improvement of serum noncholesterol sterols may indicate retarded progression of primary biliary cirrhosis (PBC) in a randomized placebo controlled two-year trial with colchicine and ursodeoxycholic acid
46. High cholestanol and low campesterol-to-sitosterol ratio in serum of patients with primary biliary cirrhosis before liver transplantation
47. High serum cholestanol and low campesterol/sitosterol ratio indicate severe liver damage and liver transplantation in primary biliary cirrhosis